GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Cash Flow from Investing

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Cash Flow from Investing : $-29.07 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Tonix Pharmaceuticals Holding spent $0.44 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $0.01 Mil from other investing activities. In all, Tonix Pharmaceuticals Holding spent $0.43 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Tonix Pharmaceuticals Holding Cash Flow from Investing Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Cash Flow from Investing Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -8.56 -35.31 -48.15 -29.07

Tonix Pharmaceuticals Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.67 -3.80 -24.02 -0.82 -0.43

Tonix Pharmaceuticals Holding Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Tonix Pharmaceuticals Holding's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Tonix Pharmaceuticals Holding's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tonix Pharmaceuticals Holding  (NAS:TNXP) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Tonix Pharmaceuticals Holding's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.44 Mil. It means Tonix Pharmaceuticals Holding spent $0.44 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Tonix Pharmaceuticals Holding's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Tonix Pharmaceuticals Holding gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Tonix Pharmaceuticals Holding's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Tonix Pharmaceuticals Holding spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Tonix Pharmaceuticals Holding's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Tonix Pharmaceuticals Holding gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Tonix Pharmaceuticals Holding's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Tonix Pharmaceuticals Holding spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Tonix Pharmaceuticals Holding's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Tonix Pharmaceuticals Holding gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Tonix Pharmaceuticals Holding's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Tonix Pharmaceuticals Holding paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Tonix Pharmaceuticals Holding's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Tonix Pharmaceuticals Holding paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Tonix Pharmaceuticals Holding's cash from other investing activities for the three months ended in Dec. 2023 was $0.01 Mil. It means Tonix Pharmaceuticals Holding received $0.01 Mil from other investing activities.


Tonix Pharmaceuticals Holding Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Traded in Other Exchanges
N/A
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.
Executives
Richard Newcomb Stillwell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman director, 10 percent owner, officer: Chief Executive Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan officer: Chief Medical Officer C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange director
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris officer: Chief Administrative Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes director 74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Headlines

From GuruFocus